Monday, December 8, 2014
Agilent Technologies, headquartered in Santa Clara, Calif., and Houston, Texas-based Baylor College of Medicine have opened the Agilent Technologies Mass Spectrometry Center of Excellence as part of the Alkek Center for Molecular Discovery and the Baylor College of Medicine Core Laboratory in the college’s department of molecular and cellular biology.
Aldeyra Therapeutics, a Massachusetts-based biotechnology company focused on the development of products to treat diseases related to free aldehydes, is collaborating with the National Organization for Rare Disorders (NORD), a U.S. nonprofit organization dedicated to helping people with rare diseases.
The Pulse on Study Conduct by Elizabeth Weeks-Rowe
The Study Coordinator (SC)-CRA relationship is pivotal to site success.
Pharmacyclics, a Sunnyvale, Calif.-based biopharmaceutical company, has launched informCLL, a large, observational, prospective registry that will explore the natural history of chronic lymphocytic leukemia (CLL), examine how Imbruvica (ibrutinib) and other approved targeted therapies are being used to treat patients with CLL and provide a comparison to treatments using conventional chemoimmunotherapy (CIT). Imbruvica is being jointly developed and commercialized by Pharmacyclics and Janssen Biotech, and the registry is a joint effort between the companies. Registry enrollment will begin in the first half of 2015.
INC Research Holdings, a global phase I-IV CRO headquartered in Raleigh, N.C., has announced an expanded partnership with the Society for Clinical Research Sites (SCRS), an Ellicott City, Md.-based global trade organization, to become the society’s first Circle of Sustainability Sponsor, reinforcing the INC’s commitment to fostering strong site relationships globally.